Table1_Prevention and Recovery of COVID-19 Patients With Kampo Medicine: Review of Case Reports and Ongoing Clinical Trials.pdf

Coronavirus disease 2019 (COVID-19) spread to Japan in 2020, where the number of infected patients exceeded 250,000 and COVID-related deaths exceeded 3,500 in one year. Basic guidelines for infection control were implemented in Japan, and research and development of effective drugs and vaccines were promoted. This included considering Kampo medicine, which has a long history of treating recurring emerging viral infections. Considering the characteristics of the disease (inflammation of the upper and lower respiratory tract as well as potential neural damage and vasculitis), Kampo medicine could be considered as a treatment strategy due to its antiviral and anti-inflammatory effects induced by multiple active substances that could aid in disease prevention and recovery. In this study, case reports on the management of COVID-19 with Kampo medicine, which were published until March 31, 2021, were reviewed. The search strategy involved the use of Medline and hand-searching. Twenty two patients were treated using Kampo medicines with or without Western medicine, based on individual conditions. On the other hand, the effects of Kampo medicines as a potential preventive treatment (pre-infection), active treatment (especially in the acute and subacute stage), or treatment of sequelae to aid recovery (after infection) in the different stages of COVID-19 are being studied as research projects in the Japan Society for Oriental Medicine (JSOM). JSOM has also organized a pioneering project of clinical trials for COVID-19, some of which are now in progress.

2019冠状病毒病（COVID-19）于2020年传入日本，一年内感染患者人数超过25万，COVID相关死亡人数超过3500人。日本实施了基本感染防控指南，并推动了有效药物和疫苗的研发。这其中包括了对汉方医学的考量，汉方医学在治疗反复出现的突发病毒感染方面拥有悠久的历史。鉴于疾病的特征（上呼吸道和下呼吸道的炎症，以及潜在的神经损伤和血管炎），由于其由多种活性成分诱导的抗病毒和抗炎作用，汉方医学可以作为治疗策略被考虑，以助于疾病的预防和康复。在本研究中，回顾了截至2021年3月31日发表的关于使用汉方医学治疗COVID-19的病例报告。搜索策略包括使用Medline数据库和手工检索。共22名患者接受了汉方药物的治疗，部分患者同时接受了西医治疗，根据个体情况而定。另一方面，日本汉方医学会（JSOM）正在作为研究项目研究汉方药物作为潜在预防治疗（感染前）、积极治疗（尤其是在急性期和亚急性期）或治疗后遗症以促进康复（感染后）在COVID-19不同阶段的效果。JSOM还组织了一项针对COVID-19的先驱临床试验项目，其中一些项目目前正在进行中。